Expertendialog: Neuroendokrine Tumore der Lunge und des gastroenteropankreatischen Systems

Hörsch, Dieter; Sayeg, Y.; Bonnet, R.; Kaemmerer, Daniel; Presselt, N.; Baüm, Richard

doi:10.1055/s-0031-1291478

Cited by 9 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distinction between the four BP-NEN entities is clinically very important because the subsequent classification-based diagnostic and therapeutic approaches differ due to their differential aggressiveness [3, 5, 6, 29, 30]. Mitosis counting is part of the classification procedure (based on the WHO and IASLC criteria); it is a very time-consuming process, and has a relatively high inter-observer variability [6, 8, 9].…”

Section: Discussionmentioning

confidence: 99%

Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects

Neubauer

Wirtz²,

Kaemmerer

et al. 2016

Oncotarget

View full text Add to dashboard Cite

The classification of bronchopulmonary neuroendocrine neoplasms (BP-NEN) into four tumor entities (typical carcinoids (TC), atypical carcinoids (AC), small cell lung cancers (SCLC), large cell neuroendocrine lung carcinomas (LCNEC)) is difficult to perform accurately, but important for prognostic statements and therapeutic management decisions. In this regard, we compared the expression of three proliferation markers, Ki-67, Topoisomerase II alpha (TOP2A), and RacGAP1, in a series of tumor samples from 104 BP-NEN patients (24 TC, 21 AC, 52 SCLC, 7 LCNEC) using different evaluation methods (immunohistochemistry (IHC): Average evaluation, Hotspot evaluation, digital image analysis; RT-qPCR).The results indicated that all three markers had increased protein and mRNA expression with poorer differentiation and correlated well with each other, as well as with grading, staging, and poor survival. Compared with Ki-67 and TOP2A, RacGAP1 allowed for a clearer prognostic statement. The cut-off limits obtained for Ki-67-Average (IHC) were TC-AC 1.5, AC-SCLC 19, and AC-LCNEC 23.5. The Hotspot evaluation generated equal to higher, the digital image analysis generally lower between-entity cut-off limits.All three markers enabled a clear-cut differentiation between the BP-NEN entities, and all methods evaluated were suitable for marker assessment. However, to define optimal cut-off limits, the Ki-67 evaluation methods should be standardized. RacGAP1 appeared to be a new marker with great potential.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects

Neubauer

Wirtz²,

Kaemmerer

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Hence, the Ft-phenotype found in TC/AC provides the rationale for the administration of pemetrexed for the treatment of unresectable or metastatic TC and AC, which commonly occur at a very low frequency (1 TC and 2 AC in our study collective). Discussions about the efficacy of cisplatin/etoposide in this setting are ongoing [ 56 ] and no standard-of-care for chemotherapy exists. Three of the investigated carcinoids showed spread to regional lymph nodes indicating an aggressive subtype of a rather low-grade tumor.…”

Section: Discussionmentioning

confidence: 99%

Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome

et al. 2016

View full text Add to dashboard Cite

Purpose25% of all lung cancer cases are neuroendocrine (NELC) including typical (TC) and atypical carcinoid (AC), large-cell neuroendocrine (LCNEC) and small cell lung cancer (SCLC). Prognostic and predictive biomarkers are lacking.Experimental DesignSixty patients were used for nCounter mRNA expression analysis of the folic-acid metabolism (ATIC, DHFR, FOLR1, FPGS, GART, GGT1, SLC19A1, TYMS) and DNA-repair (ERCC1, MLH1, MSH2, MSH6, XRCC1). Phenotypic classification classified tumors (either below or above the median expression level) with respect to the folic acid metabolism or DNA repair.ResultsExpression of FOLR1, FPGS, MLH1 and TYMS (each p<0.0001) differed significantly between all four tumor types. FOLR1 and FPGS associated with tumor differentiation (both p<0.0001), spread to regional lymph nodes (FOLR1 p=0.0001 and FPGS p=0.0038), OS and PFS (FOLR1 p<0.0050 for both and FPGS p<0.0004 for OS).Phenotypic sorting revealed the Ft-phenotype to be the most prominent expression profile in carcinoids, whereas SCLC presented nearly univocal with the fT and LCNEC with fT or ft. These results were significant for tumor subtype (p<0.0001).ConclusionsThe assessed biomarkers and phenotypes allow for risk stratification (OS, PFS), diagnostic classification and enhance the biological understanding of the different subtypes of neuroendocrine tumors revealing potential new therapy options and clarifying known resistance mechanisms.

show abstract

“…The high spatial resolution of current CT scanners allows to show the relation between the pancreatic duct and tumor in the GEP [23][24]. In general for abdominal imaging, MRI is superior to CT because of the better soft tissue contrast.…”

Section: Computed Tomographymentioning

confidence: 99%

68Ga-Somatostatin Analogue PET/CT in Neuroendocrine Tumors

Giovannini¹,

Gaeta²,

Ciarmiello³

2014

J Diagn Imaging Ther

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) include a spectrum of neoplasms characterized by histologic heterogeneity with significant clinical differences. Generally are well differentiated tumors but often present metastases at diagnosis. Conventional imaging techniques result insufficient in early diagnosis and therapy monitoring. Standardized morphological criteria to assess treatment response are inadequate in NETs, because of their biologic evolution and the cytostatic nature of new oncologic treatments. Functional imaging modalities have improved the understanding and diagnosis of NETs by the use of somatostatin analogue tracers labelled with radioisotopes.111 In-Octreotide scintigraphy was considered the gold standard imaging modalities for NET detection with a diagnostic accuracy approximately of 90%. Actually 68 Ga-Dota-SST radiotracers (SSTRTs) PET/CT represent a superior imaging procedure with higher accuracy in detection of NET lesions as compared to morphological imaging procedures and somatostatin receptor scintigraphy. Additionally, the use of somatostatin analogue radiolabelled tracers offers the possibility to non-invasively evaluate the presence of somatostatin receptor expression on NET cells, with direct therapeutic implications. However, in the management of patients with NETs and in the evaluation of response to therapy the specialists

show abstract

Expertendialog: Neuroendokrine Tumore der Lunge und des gastroenteropankreatischen Systems

Abstract: InstituteDie Institutsangaben sind am Ende des Beitrags gelistet.

Cited by 9 publications

References 7 publications

Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects

Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects

Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome

68Ga-Somatostatin Analogue PET/CT in Neuroendocrine Tumors

Contact Info

Product

Resources

About